肝脏原发性状细胞癌的免疫疗法:一个病例报告
Jian Jiang1, Guomin Dong1, Suoni Li2
1Graduate School, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, P.R. China.
Oncology letters
|April 17, 2025
概括
本案例研究详细介绍了一名72岁男子罕见的肝脏原发性平细胞癌 (PSCCL). 患者对包括envafolimab.com在内的新型组合疗法取得了持续的部分反应.
科学领域:
- 肝胆道恶性瘤 肝胆道恶性瘤
- 在瘤学瘤学.
- 罕见的癌症 罕见的癌症
背景情况:
- 肝脏原发性状细胞癌 (PSCCL) 是一种非常罕见的肝脏恶性瘤.
- 由于PSCCL的罕见性,诊断和治疗带来了重大的临床挑战.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.7K
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
348
